Parental acceptance of Human Papillomavirus vaccines
- 31 March 2008
- journal article
- Published by Elsevier BV in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 137 (1), 103-107
- https://doi.org/10.1016/j.ejogrb.2007.02.012
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trialThe Lancet, 2006
- Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trialThe Lancet Oncology, 2005
- Carcinogenicity of human papillomavirusesThe Lancet Oncology, 2005
- The epidemiology of human papillomavirus infectionsJournal of Clinical Virology, 2005
- Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trialThe Lancet, 2004
- Epidemiological and clinical aspects of human papillomavirus detection in the prevention of cervical cancerReviews in Medical Virology, 2004
- Chapter 1: Human Papillomavirus and Cervical Cancer--Burden and Assessment of CausalityJNCI Monographs, 2003
- A Controlled Trial of a Human Papillomavirus Type 16 VaccineThe New England Journal of Medicine, 2002
- Public health paradoxes and the epidemiological impact of an HPV vaccineJournal of Clinical Virology, 2000
- Human papillomavirus is a necessary cause of invasive cervical cancer worldwideThe Journal of Pathology, 1999